Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Monk

Showing results (241-250 of 738) with videos related to

Pageof 74
Sort By:
Gynecologic Oncology|December 15, 2010
Docetaxel plus trabectedin appears active in recurrent or persistent ovarian and primary peritoneal cancer after up to three prior regimens: a phase II study of the Gynecologic Oncology GroupBradley J Monk, Michael W Sill, Parviz Hanjani, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 19, 2005
Randomized comparison of weekly cisplatin or protracted venous infusion of fluorouracil in combination with pelvic radiation in advanced cervix cancer: a gynecologic oncology group studyRachelle Lanciano, Alison Calkins, Brian N Bundy, et al.
The New Zealand Medical Journal|September 18, 2025
Introducing the Hauora Māori Equity Toolkit for Specialist Healthcare Services (HMET-SHS)Maira Patu, Melissa Kerdemelidis, Nadia Summers, et al.
Frontiers in Oncology|November 2, 2023
Overcoming the challenges of drug development in platinum-resistant ovarian cancerRamez N Eskander, Kathleen N Moore, Bradley J Monk, et al.
Gynecologic Oncology|November 25, 1998
In vitro phase II comparison of the cytotoxicity of a novel platinum analog, nedaplatin (254-S), with that of cisplatin and carboplatin against fresh, human cervical cancersB J Monk, D S Alberts, R A Burger, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|October 31, 2023
The promise of combining CDK4/6 inhibition with hormonal therapy in the first-line treatment setting for metastatic or recurrent endometrial adenocarcinomaIsabelle Ray-Coquard, Bradley J Monk, Domenica Lorusso, et al.
The Oncologist|September 4, 2023
Left Ventricular Ejection Fraction in Patients With Ovarian Cancer Treated With Avelumab, Pegylated Liposomal Doxorubicin, or BothMarc P Bonaca, Javid J Moslehi, Jonathan A Ledermann, et al.
Gynecologic Oncology Reports|December 15, 2020
Clinical trials, adaptability and the COVID-19 pandemicRamez N Eskander, Bhavana Pothuri, Leslie Randall, et al.
Gynecologic Oncology|February 18, 1999
Protein kinase C isoform expression and activity alter paclitaxel resistance in vitroL Chen, R A Burger, G M Zaunbrecher, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 2, 2009
Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group studyBradley J Monk, Michael W Sill, D Scott McMeekin, et al.
Pageof 74

Showing results (241-250 of 738) with videos related to

Sort By:
Pageof 74
Gynecologic Oncology|December 15, 2010
Docetaxel plus trabectedin appears active in recurrent or persistent ovarian and primary peritoneal cancer after up to three prior regimens: a phase II study of the Gynecologic Oncology GroupBradley J Monk, Michael W Sill, Parviz Hanjani, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 19, 2005
Randomized comparison of weekly cisplatin or protracted venous infusion of fluorouracil in combination with pelvic radiation in advanced cervix cancer: a gynecologic oncology group studyRachelle Lanciano, Alison Calkins, Brian N Bundy, et al.
The New Zealand Medical Journal|September 18, 2025
Introducing the Hauora Māori Equity Toolkit for Specialist Healthcare Services (HMET-SHS)Maira Patu, Melissa Kerdemelidis, Nadia Summers, et al.
Frontiers in Oncology|November 2, 2023
Overcoming the challenges of drug development in platinum-resistant ovarian cancerRamez N Eskander, Kathleen N Moore, Bradley J Monk, et al.
Gynecologic Oncology|November 25, 1998
In vitro phase II comparison of the cytotoxicity of a novel platinum analog, nedaplatin (254-S), with that of cisplatin and carboplatin against fresh, human cervical cancersB J Monk, D S Alberts, R A Burger, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|October 31, 2023
The promise of combining CDK4/6 inhibition with hormonal therapy in the first-line treatment setting for metastatic or recurrent endometrial adenocarcinomaIsabelle Ray-Coquard, Bradley J Monk, Domenica Lorusso, et al.
The Oncologist|September 4, 2023
Left Ventricular Ejection Fraction in Patients With Ovarian Cancer Treated With Avelumab, Pegylated Liposomal Doxorubicin, or BothMarc P Bonaca, Javid J Moslehi, Jonathan A Ledermann, et al.
Gynecologic Oncology Reports|December 15, 2020
Clinical trials, adaptability and the COVID-19 pandemicRamez N Eskander, Bhavana Pothuri, Leslie Randall, et al.
Gynecologic Oncology|February 18, 1999
Protein kinase C isoform expression and activity alter paclitaxel resistance in vitroL Chen, R A Burger, G M Zaunbrecher, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 2, 2009
Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group studyBradley J Monk, Michael W Sill, D Scott McMeekin, et al.
Pageof 74